<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="to Pandemic The Coronavirus Disease 19 (COVID-19) is a highly" exact="infectious disease" post="caused by a novel coronavirus, Severe Acute Respiratory Syndrome"/>
 <result pre="and avoid the adverse effects of COVID-19 in people with" exact="liver disease." post="Given the global burden of chronic liver disease, this"/>
 <result pre="people with liver disease. Given the global burden of chronic" exact="liver disease," post="this pandemic could further worsen the treatment of patients"/>
 <result pre="failure [35]. In a recent meta-analysis, the prevalence of chronic" exact="liver disease" post="(CLD) patients (73 studies, 24,299 patients) was 3% among"/>
 <result pre="that sepsis is not uncommon in patients with existing liver" exact="cirrhosis" post="[39], suggesting that pneumonia associated hypoxia is one of"/>
 <result pre="uncommon in patients with existing liver cirrhosis [39], suggesting that" exact="pneumonia" post="associated hypoxia is one of the most significant factors"/>
 <result pre="Worst COVID-19 Outcome Due to systemic immunodeficiency, patients with chronic" exact="liver disease" post="and cirrhosis may have a higher risk of COVID-19"/>
 <result pre="Due to systemic immunodeficiency, patients with chronic liver disease and" exact="cirrhosis" post="may have a higher risk of COVID-19 infections [42]."/>
 <result pre="due to immunosuppressive therapy [43,44]. However, the relationship between underlying" exact="liver disease" post="and COVID-19 has not been fully studied. Patients with"/>
 <result pre="disease and COVID-19 has not been fully studied. Patients with" exact="cirrhosis" post="are at an increased risk of decompensation or development"/>
 <result pre="infection [45,46]. Co-morbidities, including coronary artery disease, cerebrovascular disease, and" exact="chronic obstructive pulmonary disease," post="are more prevalent in hospitalized patients with severe/critical illnesses"/>
 <result pre="triggered by COVID-19 in patients with a pre-existing history of" exact="liver disease" post="(especially older patients). 5. Hepatoprotective Agents Most of the"/>
 <result pre="benefits in acute and chronic viral, alcohol, and chemically induced" exact="hepatitis" post="[61]. Silymarin is the most frequently used natural compound"/>
 <result pre="that pretreatment with extracts restored antioxidant enzyme levels in GalN/LPS-treated" exact="hepatitis" post="in animal models [93]. Furthermore, it is known to"/>
 <result pre="plant is a very effective treatment for chest disease and" exact="asthma" post="[56]. Studies have shown hepatoprotective activity of G. glabra"/>
 <result pre="a large variety of viruses, including HIV-1, HSV-2, HPV and" exact="hepatitis" post="virus [140,141]. 5.9. Other Hepatoprotective Agents Capparis spinosa, generally"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 26.ShiH.HanX.JiangN.CaoY.AlwalidO.GuJ.FanY.ZhengC.Radiological findings from"/>
 <result pre="A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 26.ShiH.HanX.JiangN.CaoY.AlwalidO.GuJ.FanY.ZhengC.Radiological findings from 81 patients with COVID-19" exact="pneumonia" post="in Wuhan, China: A descriptive studyLancet Infect Dis20202042543410.1016/S1473-3099(20)30086-432105637 27.WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.WangB.XiangH.ChengZ.XiongY.et"/>
 <result pre="in coronavirus-associated severe acute respiratory syndromeKidney Int.20056769870510.1111/j.1523-1755.2005.67130.x15673319 36.KovalicA.J.SatapathyS.K.ThuluvathP.J.Prevalence of chronic" exact="liver disease" post="in patients with COVID-19 and their clinical outcomes: A"/>
 <result pre="liver failureJ. Hepatol.20197079779910.1016/j.jhep.2018.11.01530635243 46.QiuH.WanderP.BernsteinD.SatapathyS.K.Acute on chronic liver failure from novel" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2)Liver International.2020401590159310.1111/liv.1450632369658 47.KovalicA.J.HuangG.ThuluvathP.J.SatapathyS.K.Elevated Liver Biochemistries in Hospitalized"/>
 <result pre="activity of a trans-chalcone against hydrogen peroxide induced toxicity in" exact="hepatocellular carcinoma" post="(HepG2) cellsAsian Pac. J. Cancer Prev.2011122513251622320949 50.SikanderM.MalikS.ParveenK.AhmadM.YadavD.Bin HafeezZ.BansalM.Hepatoprotective effect"/>
 <result pre="Res.20046111111710.1016/j.antiviral.2003.09.00514670584 108.CranceJ.-M.LÃ©vÃ¨queF.BiziagosE.Van Cuyck-GandrÃ©H.JouanA.DeloinceR.Studies on mechanism of action of glycyrrhizin against" exact="hepatitis" post="a virus replication in vitroAntivir. Res.199423637610.1016/0166-3542(94)90033-78141593 109.CranceJ.M.BiziagosE.PassagotJ.Van Cuyck-GandrÃ©H.DeloinceR.Inhibition of"/>
 <result pre="hepatitis a virus replication in vitroAntivir. Res.199423637610.1016/0166-3542(94)90033-78141593 109.CranceJ.M.BiziagosE.PassagotJ.Van Cuyck-GandrÃ©H.DeloinceR.Inhibition of" exact="hepatitis" post="A virus replication in vitro by antiviral compoundsJ. Med"/>
 <result pre="C Virus In VitroPLoS ONE20138e6899210.1371/journal.pone.006899223874843 113.MichaelisM.GeilerJ.NaczkP.SithisarnP.OgbomoH.AltenbrandtB.LeutzA.DoerrH.W.CinatlJ.CinatlJ.Glycyrrhizin inhibits highly pathogenic H5N1" exact="influenza" post="A virus-induced pro-inflammatory cytokine and chemokine expression in human"/>
 <result pre="genome RNA, mRNA and protein synthesesDrug Discov. Ther.20171124625210.5582/ddt.2017.0104829070744 116.WolkerstorferA.KurzH.BachhofnerN.SzolarO.H.Glycyrrhizin inhibits" exact="influenza" post="A virus uptake into the cellAntivir. Res.20098317117810.1016/j.antiviral.2009.04.01219416738 117.ChenL.HuC.HoodM.ZhangX.ZhangL.KanJ.DuJ.A Novel"/>
 <result pre="miceJ. Ethnopharmacol.200711350350910.1016/j.jep.2007.07.01717720339 122.VenkateswaranP.S.MillmanI.BlumbergB.S.Effects of an extract from Phyllanthus niruri on" exact="hepatitis" post="B and woodchuck hepatitis viruses: In vitro and in"/>
 <result pre="an extract from Phyllanthus niruri on hepatitis B and woodchuck" exact="hepatitis" post="viruses: In vitro and in vivo studiesProc. Natl. Acad."/>
 <result pre="HPV oncogenes and upregulation of tumor suppressor proteins in human" exact="cervical cancer" post="cellsCarcinogenesis2011321697170510.1093/carcin/bgr19221859835 131.PantM.AmbwaniT.UmapathiV.Antiviral Activity of Ashwagandha Extract on Infectious Bursal"/>
 <result pre="oncogenes and upregulation of tumor suppressor proteins in human cervical" exact="cancer" post="cellsCarcinogenesis2011321697170510.1093/carcin/bgr19221859835 131.PantM.AmbwaniT.UmapathiV.Antiviral Activity of Ashwagandha Extract on Infectious Bursal"/>
 <result pre="CURCUMINResults Probl. Cell Differ.200759521322610.1007/978-0-387-46401-5_9 137.KimY.S.YoungM.R.BobeG.ColburnN.H.MilnerJ.A.Bioactive food components, inflammatory targets, and" exact="cancer" post="preventionCancer Prev. Res.2009220020810.1158/1940-6207.CAPR-08-014119258539 138.SurhY.J.ChunK.S.Cancer chemopreventive effects of curcuminThe Molecular"/>
 <result pre="Curcumin in Health and DiseaseSpringerBoston, MA, USA2007149172 139.BruckR.AshkenaziM.WeissS.GoldinerI.ShapiroH.AeedH.GeninaO.HelpernZ.PinesM.Prevention of liver" exact="cirrhosis" post="in rats by curcuminLiver Int20072737338310.1111/j.1478-3231.2007.01453.x17355460 140.DasS.SarmahS.LyndemS.Singha RoyA.An investigation into"/>
 <result pre="replication, antipyretics induced toxicity, hypoxia, antiviral induced toxicity, and pre-existing" exact="liver disease." post="Figure 4 Various medicinal plants possessing potential hepatoprotective activities."/>
</results>
